Beam Therapeutics Inc

16 de out. de 2026, 23:41 UTC

Beam Therapeutics Inc is advancing in after-market trading, rising sharply from earlier lows to its highest cumulative return.

15 de out. de 2026, 22:01 UTC

Beam Therapeutics Inc. shares are trading lower in after-market hours, declining from slightly negative to more negative since Thursday's close.

14 de out. de 2026, 19:31 UTC

Beam Therapeutics declines amid market volatility; Wedbush reiterates Outperform rating with a $65 price target and upcoming presentation of BEAM-301 trial data.

13 de out. de 2026, 23:36 UTC

Beam Therapeutics to present initial data from its Phase 1/2 trial of BEAM-301 for glycogen storage disease type Ia at a conference in October 2026.

12 de out. de 2026, 22:51 UTC

Beam Therapeutics Inc shares fell significantly in after-market trading, reaching their lowest point since Monday's close, following a gradual decline throughout the session.

9 de out. de 2026, 20:07 UTC

Beam Therapeutics shares are advancing, supported by a rise in the iShares Biotechnology ETF amid gains in key holdings, despite earlier session pullbacks.

8 de out. de 2026, 21:10 UTC

Beam Therapeutics Inc is experiencing a notable decline in after-market trading, continuing a trend of four consecutive lower daily closes.

6 de out. de 2026, 20:07 UTC

Beam Therapeutics Inc shares are declining amid a broader biotechnology sector downturn, influenced by sharp losses in the ARK Genomic Revolution ETF and CRISPR Therapeutics AG.

5 de out. de 2026, 23:46 UTC

Beam Therapeutics Inc saw a modest decline in after-market trading, pulling back from earlier highs while remaining above its 20-day moving average.

2 de out. de 2026, 20:07 UTC

Beam Therapeutics Inc shares are rising amid a broadly advancing market, supported by lower U.S. Treasury yields and recalibrated interest rate expectations.

1 de out. de 2026, 20:07 UTC

Beam Therapeutics shares fell amid broader biotechnology sector weakness, influenced by declines in the SPDR S&P Biotech ETF and disappointing results from Nektar Therapeutics.

30 de set. de 2026, 20:07 UTC

Beam Therapeutics Inc filed a lawsuit against a former scientist and two biotech firms for alleged theft of its gene-editing therapy, as shares fell modestly.

29 de set. de 2026, 20:07 UTC

Beam Therapeutics has filed a lawsuit against YolTech and Serapha Bio for trade secret misappropriation, as shares trade higher amid rising Prime Medicine stock.

28 de set. de 2026, 23:05 UTC

Beam Therapeutics Inc's shares declined modestly in after-market trading, falling from an early session high and trading below its 20-day moving average.

24 de set. de 2026, 20:07 UTC

Beam Therapeutics is advancing, likely in sympathy with the ARK Genomic Revolution ETF, which is higher following strong performances from its holdings.

23 de set. de 2026, 20:07 UTC

Beam Therapeutics Inc shares fell sharply, potentially influenced by declines in the Direxion Daily S&P Biotech Bull 3X ETF amid broader market weakness.

22 de set. de 2026, 19:15 UTC

Beam Therapeutics Inc has achieved four consecutive sessions of gains, reaching a peak return earlier today, though it remains below its 20-day moving average.

21 de set. de 2026, 23:06 UTC

Beam Therapeutics Inc saw a slight gain in after-market trading, fluctuating positively but remaining below its 20-day moving average and near the lower end of its one-month range.

18 de set. de 2026, 19:56 UTC

Beam Therapeutics Inc is trading higher amid modest gains, despite remaining significantly below its 20-day moving average following unchanged U.S. industrial production data.

17 de set. de 2026, 23:01 UTC

Beam Therapeutics Inc is advancing in after-market trading, rebounding from earlier lows and maintaining upward momentum alongside Editas Medicine Inc.

16 de set. de 2026, 23:06 UTC

Beam Therapeutics Inc is trading roughly flat in after-market hours, impacted by broader biotechnology sector weakness, while CRISPR Therapeutics AG is slightly higher.

15 de set. de 2026, 23:01 UTC

Beam Therapeutics Inc is trading higher in after-market hours, reflecting broader market trends. No specific company news was identified to explain this movement.

14 de set. de 2026, 20:08 UTC

Beam Therapeutics Inc is advancing during Monday's session, recovering from earlier losses as discussions around Phase 2 data on alpha-1 antitrypsin deficiency continue.

11 de set. de 2026, 23:06 UTC

Beam Therapeutics shares are higher in after-market trading, likely influenced by a rise in CRISPR Therapeutics following a narrower-than-expected U.S. budget deficit.

10 de set. de 2026, 23:11 UTC

Beam Therapeutics Inc shares declined in after-market trading, marking the fourth consecutive session of losses and closing significantly below their 20-day moving average.

9 de set. de 2026, 23:06 UTC

Beam Therapeutics shares are trading higher in after-market hours following a presentation at Citigroup's Biopharma Summit, highlighting advancements in its pipeline.

8 de set. de 2026, 20:03 UTC

Beam Therapeutics shares are lower despite presenting promising clinical data for BEAM-302 therapy at the European Respiratory Society Congress, amid regulatory concerns.

4 de set. de 2026, 23:00 UTC

Beam Therapeutics Inc shares are trading higher in after-market hours, continuing a steady increase since Friday's close amid mixed economic signals.

1 de set. de 2026, 19:36 UTC

Beam Therapeutics appointed Eric Foster as chief commercial officer. Shares are trading lower despite the leadership change amid preparations for a 2027 product launch.

31 de ago. de 2026, 19:16 UTC

Beam Therapeutics Inc. shares are trading roughly flat, with no specific news identified. The stock remains above its 20-day moving average.